Porter Stansberry, founder of Stansberry Research, estimates Bitcoin's fair value at $134,000, significantly above its current price near $75,000. He attributes this gap to risk capital shifting aggressively into tech stocks like Nvidia, leaving Bitcoin largely ignored. Stansberry's model links Bitcoin's value directly to banking liquidity and monetary expansion, unlike gold which tracks credit growth. He sees current monetary conditions as favorable for Bitcoin's rise, calling this the best buying opportunity in a decade. Meanwhile, his gold price model forecasts $8,000 per ounce by 2030, but Bitcoin offers a better entry point given its undervaluation. Stansberry also warns of a 2029 financial reset driven by government deficits and dollar debasement, positioning Bitcoin and gold as key hedges against purchasing power loss.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
